DelveInsight’s “IgA Nephropathy Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the IgA Nephropathy pipeline landscape. It covers the IgA Nephropathy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the IgA Nephropathy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the IgA Nephropathy Pipeline? @ https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight
Key Takeaways from the IgA Nephropathy Pipeline Report
Want to know which companies are leading innovation in IgA Nephropathy? @ IgA Nephropathy Clinical Trials Assessment
The IgA Nephropathy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The IgA Nephropathy Pipeline Report also highlights the unmet needs with respect to the IgA Nephropathy.
IgA Nephropathy Overview
IgA nephropathy (IgAN), or Berger’s disease, is the most common primary glomerular disease that can progress to end stage renal failure (ESRD). Because of the critical interaction between an intrinsic antigen (galactose-deficient IgA1) and circulating anti-glycan antibodies, IgA nephropathy can be considered an autoimmune disease. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. This condition most often occurs in Caucasian and Asian males. It usually appears when people are in their teens to late 30s but can occur at any age. Many cases resolve over time. However, in a subset of patients, the disease may not resolve and thus can lead to end-stage renal disease (ESRD) after 20-25 years. Rarely the condition can progress much more rapidly leading to renal failure within a few years, if not treated.
IgA Nephropathy Emerging Drugs Profile
Zigakibart is a humanized IgG4 monoclonal antibody that binds the cytokine A Proliferation-Inducing Ligand (APRIL, also known as TNFSF13). APRIL is a critical factor in immunoglobulin (Ig) A nephropathy pathogenesis. By targeting APRIL, zigakibart interferes with B-cell differentiation and the survival of Gd-IgA1–producing plasma cells, thereby leading to decreased Gd-IgA1 levels and consequently reducing immune complex formation, thus exhibiting disease-modifying potential in IgAN. Novartis Pharmaceuticals is currently investigating Zigakibart in Phase III clinical trials for IgA Nephropathy.
BHV-1400 is a potential first-in-class Gd-IgA1 TRAP degrader, rationally designed to leverage the body’s natural hepatic clearance mechanisms to selectively target and remove Gd-IgA1, the underlying cause of the IgA nephropathy and IgA vasculitis. BHV-1400 spares IgG, IgA, IgE, and IgM to preserve patient immune protection against bacteria, viruses and parasites. Currently, according to the company’s pipeline the drug is being evaluated in the Phase I/II stage of its development for the treatment of IgA Nephropathy.
TST 008 is a first-in-class bispecific antibody combining MASP2 antibody with another molecule blocking B-cell activation and/or differentiation. It act as Immunogenetic modulators. It acts by targeting both the lectin complement pathway and B-cell regulation pathway. TST008 binds to Mannan-binding lectin-associated serine protease-2 (MASP2). By blocking MASP2, TST008 inhibits the lectin pathway of the complement cascade, which is involved in driving inflammatory processes in autoimmune diseases. The molecule is fused with a truncated transmembrane activator and calcium modulator ligand interactor (TACI) protein. This TACI component allows the antibody to bind to ligands such as BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand). The drug is being evaluated in preclinical stage of its development for the treatment of IgA Nephropathy.
If you’re tracking ongoing IgA Nephropathy Clinical trials, this press release is a must-read @ IgA Nephropathy Treatment Drugs
The IgA Nephropathy Pipeline report provides insights into:-
IgA Nephropathy Companies
Novartis Pharmaceuticals, Biohaven Ltd., Keymed Biosciences Co. Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd., ADARx Pharmaceuticals Inc., Biogen, Suzhou Rigerna Therapeutics, Wuxi BioCity Biopharmaceutics Co., Ltd., Transcenta Holding, Climb Bio, Chengdu Suncadia Medicine Co., Ltd., Purespring Therapeutics and others.
IgA Nephropathy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
IgA Nephropathy Products have been categorized under various Molecule types such as,
From emerging drug candidates to competitive intelligence, the IgA Nephropathy Pipeline Report covers it all @ IgA Nephropathy Market Drivers and Barriers, and Future Perspectives
Scope of the IgA Nephropathy Pipeline Report
Discover what’s next for the IgA Nephropathy Treatment landscape in this detailed analysis @ IgA Nephropathy Emerging Drugs and Major Players
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/iga-nephropathy-igan-pipeline-insight
